{"log_id": 2747690646453182499, "direction": 0, "words_result_num": 49, "words_result": [{"probability": {"variance": 0.025206, "average": 0.907467, "min": 0.396685}, "location": {"width": 851, "top": 204, "height": 27, "left": 190}, "words": "如果在治疗后出现血液学性(面线线血细胞计数数值证实,如中性粒细胞<1.5×109/L或血小板<75x10L)或者"}, {"probability": {"variance": 0.014997, "average": 0.953748, "min": 0.399847}, "location": {"width": 840, "top": 233, "height": 24, "left": 193}, "words": "在开始治疗前(第1周期)出现骨抑制。下一周期或第一周期的治疗应推迟,直到血液学指标恢复到可接受的水平"}, {"probability": {"variance": 0.002375, "average": 0.979197, "min": 0.782507}, "location": {"width": 664, "top": 263, "height": 24, "left": 191}, "words": "在奥沙利铂初次治疗前和其后每个周期前要进行含有白细胞分类计数的全血细胞计数检查"}, {"probability": {"variance": 0.010518, "average": 0.962241, "min": 0.512422}, "location": {"width": 839, "top": 290, "height": 27, "left": 188}, "words": "应充分告知患者服用奥沙利铂和5氟尿嘧啶后发生版泻/呕吐、膜炎/口腔炎及中性粒细胞减少等情况的危险性"}, {"probability": {"variance": 0.016141, "average": 0.951212, "min": 0.493176}, "location": {"width": 562, "top": 320, "height": 26, "left": 189}, "words": "井与他们的医师有密切接触以保证一旦发生问题时能采取适当的措施处理之"}, {"probability": {"variance": 0.005311, "average": 0.973291, "min": 0.512822}, "location": {"width": 853, "top": 348, "height": 24, "left": 189}, "words": "如果发生黏膜炎/口腔炎。伴有或不伴有中性粒细胞减少,下次服药应推迟至黏膜炎/口腔炎恢复到至少1级。和或"}, {"probability": {"variance": 0.02755, "average": 0.909796, "min": 0.442948}, "location": {"width": 198, "top": 379, "height": 25, "left": 190}, "words": "中性粒细胞水平21.5×10°"}, {"probability": {"variance": 0.016256, "average": 0.927172, "min": 0.500921}, "location": {"width": 852, "top": 406, "height": 25, "left": 190}, "words": "奥沙利铂与5-氟尿啶(联合或不联合亚叶酸(甲酰四氢叶)合用时,应根据5-氟尿嘧啶相关的毒性对其剂量作相"}, {"probability": {"variance": 0.0036, "average": 0.962522, "min": 0.858649}, "location": {"width": 75, "top": 439, "height": 21, "left": 188}, "words": "应的调整"}, {"probability": {"variance": 0.031947, "average": 0.900944, "min": 0.380505}, "location": {"width": 850, "top": 465, "height": 25, "left": 191}, "words": "当山现严重/威胁生命(4级)的腹泻、严(34级)的中性拉细胞减少症(中性拉细胞<1x10%)严重(3~4级)的血小"}, {"probability": {"variance": 0.01437, "average": 0.94868, "min": 0.434772}, "location": {"width": 854, "top": 492, "height": 26, "left": 188}, "words": "板减少症(血小板<50x10儿)时、必须用奥沙利铂直至症状改善或消除,并且须将奥沙利铂临床应用剂量从"}, {"probability": {"variance": 0.012671, "average": 0.942805, "min": 0.449373}, "location": {"width": 767, "top": 523, "height": 25, "left": 193}, "words": "8mg/m2降到65mg/m2晚期肿瘤化疗)或至75mg/m2(轴助化疗),并且相应降低5-须尿嘧啶应用的剂"}, {"probability": {"variance": 0.019121, "average": 0.951677, "min": 0.453531}, "location": {"width": 849, "top": 552, "height": 23, "left": 192}, "words": "如果有无法解释的呼吸系统症状发生,如无痰性干咳、呼吸函难、肺泡罗所或可有放射影像学依据的肺没润,应立"}, {"probability": {"variance": 0.001417, "average": 0.986327, "min": 0.801184}, "location": {"width": 562, "top": 582, "height": 22, "left": 191}, "words": "即停止应用该药直到进一步肺部检查确定已排除发生间质性肺炎的可能为止"}, {"probability": {"variance": 0.007583, "average": 0.965653, "min": 0.538181}, "location": {"width": 849, "top": 609, "height": 25, "left": 191}, "words": "如果不能确定肝功能检查结果的异常门静脉高压症是由肝转移引起的、应考虑由奥沙利铂引起的极少见的肝血管"}, {"probability": {"variance": 1.2e-05, "average": 0.997274, "min": 0.990207}, "location": {"width": 101, "top": 641, "height": 20, "left": 190}, "words": "异常的可能性"}, {"probability": {"variance": 2.2e-05, "average": 0.996075, "min": 0.98818}, "location": {"width": 64, "top": 671, "height": 20, "left": 158}, "words": "配伍禁忌"}, {"probability": {"variance": 0.010326, "average": 0.951216, "min": 0.489532}, "location": {"width": 815, "top": 696, "height": 23, "left": 193}, "words": "不得与碱性药物或溶液(特别尼5-航尿嘧啶、碱性溶液、氨丁三醇和含轴料氨丁三醇的亚叶酸类药品)混合使用"}, {"probability": {"variance": 0.001876, "average": 0.983219, "min": 0.84666}, "location": {"width": 183, "top": 728, "height": 21, "left": 194}, "words": "不要用盐溶液配制和稀释"}, {"probability": {"variance": 0.004671, "average": 0.971521, "min": 0.67861}, "location": {"width": 768, "top": 755, "height": 23, "left": 193}, "words": "不要与其它任何药物混合或经同一个输液通道同时使用(见【用法用量】中“使用时的特殊注意事项“)"}, {"probability": {"variance": 0.007621, "average": 0.967036, "min": 0.692166}, "location": {"width": 189, "top": 785, "height": 25, "left": 193}, "words": "不要使用含铝的注射材料"}, {"probability": {"variance": 0.00024, "average": 0.990319, "min": 0.937187}, "location": {"width": 259, "top": 816, "height": 22, "left": 158}, "words": "对驾驶人员及操纵机械人员的影响"}, {"probability": {"variance": 0.009496, "average": 0.964744, "min": 0.449794}, "location": {"width": 842, "top": 842, "height": 24, "left": 200}, "words": "未对奥沙利铂对驾驶和操纵机械的能力产生的效应进行研究。但足,奥沙利铂治疗可以导致头、恐心和呕吐您"}, {"probability": {"variance": 0.009848, "average": 0.967557, "min": 0.40312}, "location": {"width": 880, "top": 860, "height": 42, "left": 155}, "words": "险性的增加,可以导致能够影响步态和平衡的神经系统症状,这可能对驾驶和纵机械的能力产生轻度或中度影响"}, {"probability": {"variance": 0.009038, "average": 0.957479, "min": 0.552387}, "location": {"width": 842, "top": 901, "height": 25, "left": 193}, "words": "视觉异常,特别是短暂性视觉丧失(停止治疗后可逆).可以影响患者驾驶和操纵机械的能力。因此、应该警告患者"}, {"probability": {"variance": 0.001536, "average": 0.982615, "min": 0.8153}, "location": {"width": 398, "top": 932, "height": 25, "left": 158}, "words": "这些事件可能对驾驶或操纵机械的能力产生潜在效应"}, {"probability": {"variance": 0, "average": 0.797124, "min": 0.797124}, "location": {"width": 48, "top": 907, "height": 70, "left": 1030}, "words": "性"}, {"probability": {"variance": 0.009912, "average": 0.948161, "min": 0.690726}, "location": {"width": 197, "top": 963, "height": 22, "left": 162}, "words": "【孕妇及咙乳期妇女用药】"}, {"probability": {"variance": 0.012116, "average": 0.955358, "min": 0.378469}, "location": {"width": 855, "top": 987, "height": 32, "left": 193}, "words": "迄今为止,尚无资料确定奥沙利铂在孕妇中使用的安全性。根据临床前的经验,临床荐剂量的奥沙利铂可以致死"}, {"probability": {"variance": 0.018846, "average": 0.941286, "min": 0.351673}, "location": {"width": 885, "top": 1018, "height": 30, "left": 160}, "words": "和或致畸。因此,在孕妇中,不主张用奥沙利铂。只有在对胎儿的危险性进行了充分的评价并征得了患者的同意后,"}, {"probability": {"variance": 0.039596, "average": 0.868054, "min": 0.449546}, "location": {"width": 153, "top": 1054, "height": 20, "left": 162}, "words": "可考比使用奥沙利伯"}, {"probability": {"variance": 0.015535, "average": 0.942223, "min": 0.502843}, "location": {"width": 597, "top": 1078, "height": 26, "left": 193}, "words": "既往未曾研究过该药物是否会通过乳汁排泄。在使用奥沙利铂彻间应当避免哺乳"}, {"probability": {"variance": 0.010423, "average": 0.953938, "min": 0.565466}, "location": {"width": 764, "top": 1107, "height": 28, "left": 193}, "words": "与其它胞毒性药物一样,对干育龄妇女思者而言,在开始奥沙利铂化疗前,应该采取有效的避孕措施"}, {"probability": {"variance": 0.000428, "average": 0.98991, "min": 0.94368}, "location": {"width": 93, "top": 1143, "height": 19, "left": 167}, "words": "【儿童用药】"}, {"probability": {"variance": 0.000199, "average": 0.993822, "min": 0.946564}, "location": {"width": 341, "top": 1168, "height": 23, "left": 196}, "words": "目前尚不确定本品在儿童中应用的安全有效性"}, {"probability": {"variance": 2.1e-05, "average": 0.996131, "min": 0.986094}, "location": {"width": 92, "top": 1200, "height": 21, "left": 168}, "words": "【老年用药】"}, {"probability": {"variance": 0.014018, "average": 0.950055, "min": 0.426391}, "location": {"width": 840, "top": 1223, "height": 30, "left": 195}, "words": "对于年龄超过65岁的患者,奥沙利铂作为单药或与5-氟尿嘧啶联合应用,都未见急性性反应的发生增加。因此,"}, {"probability": {"variance": 0.017715, "average": 0.958695, "min": 0.461841}, "location": {"width": 274, "top": 1259, "height": 22, "left": 161}, "words": "对于老年患者、没有特殊的剂调整"}, {"probability": {"variance": 3.7e-05, "average": 0.993265, "min": 0.98208}, "location": {"width": 125, "top": 1290, "height": 22, "left": 168}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.001201, "average": 0.981693, "min": 0.840931}, "location": {"width": 850, "top": 1312, "height": 32, "left": 196}, "words": "在每两周给药的患者中观察到85mg/m2奥沙利铂和输注5氟尿嘧啶之间没有药代动力学相互作用,但在每3周给予"}, {"probability": {"variance": 0.006739, "average": 0.970167, "min": 0.599475}, "location": {"width": 873, "top": 1343, "height": 30, "left": 173}, "words": "30mg/m2奥沙利铂剂量的患者中观察到5氟尿嘧啶的血浆水平约增加20%。体外试验中,下列这些药物不能取代血浆"}, {"probability": {"variance": 0.016426, "average": 0.937863, "min": 0.368161}, "location": {"width": 881, "top": 1375, "height": 27, "left": 165}, "words": "蛋白上的铂:红霉、水杨酸盐、丙戊酸钠、格拉司琼和紫杉醇。在体外研究中。奥沙利铂既不被细胞色素P450同工酶"}, {"probability": {"variance": 0.011349, "average": 0.95269, "min": 0.387361}, "location": {"width": 883, "top": 1403, "height": 31, "left": 165}, "words": "代谢,也不抑制细胞色紫P450同工酶。因此,预计在者体内不会有P450介导的药物间相互作用。由于含铂品种主要"}, {"probability": {"variance": 0.008488, "average": 0.96298, "min": 0.576792}, "location": {"width": 772, "top": 1433, "height": 30, "left": 166}, "words": "通过肾脏消除,虽还未进行特定的研究,但是合用有潜在肾毒性的化合物可能会降低这些产品的清除"}, {"probability": {"variance": 0.001255, "average": 0.980848, "min": 0.90185}, "location": {"width": 95, "top": 1470, "height": 20, "left": 169}, "words": "【药物过量】"}, {"probability": {"variance": 0.010504, "average": 0.955259, "min": 0.512166}, "location": {"width": 850, "top": 1491, "height": 33, "left": 198}, "words": "没有己知用于治疗奥沙利铂过量的解毒剂。除血小板减少外,过量使用奥沙利铂的预期并发症包括超敏反应、骨"}, {"probability": {"variance": 0.010451, "average": 0.963252, "min": 0.374485}, "location": {"width": 859, "top": 1523, "height": 30, "left": 166}, "words": "抑制、恶心、呕吐、腹泻和神经毒性。日前已有几例有关过量使用奥沙利铂的病例报告。其中观察到的不良反应为:"}, {"probability": {"variance": 0.012985, "average": 0.944556, "min": 0.395391}, "location": {"width": 880, "top": 1552, "height": 31, "left": 166}, "words": "级血小板减少(25.00m3)不伴出血、贫血、觉神经病变(如感觉异常、感觉迟钝、喉痉挛和面部肌肉痉挛)、胃"}, {"probability": {"variance": 0.009586, "average": 0.962658, "min": 0.432947}, "location": {"width": 882, "top": 1583, "height": 30, "left": 165}, "words": "肠系统疾病(如恶心、呕吐、口腔炎、肠周气胀、胀和4级肠阻)、4级脱水、呼吸困难、哮鸣、胸部疼痛、呼吸衰"}], "language": 3}